MediMix

🔬 𝗜𝗻 𝗗𝗲𝗽𝘁𝗵 𝗳𝗿𝗼𝗺 𝗘𝗡𝗘𝗧𝗦 𝟮𝟬𝟮𝟱! Prof Dr Ivan Borbath shares his insights on the 𝗖𝗢𝗠𝗣𝗘𝗧𝗘 𝘁𝗿𝗶𝗮𝗹, the 𝗳𝗶𝗿𝘀𝘁 𝗽𝗵𝗮𝘀𝗲 𝟯 𝗿𝗲𝗮𝗱-𝗼𝘂𝘁 𝗲𝘃𝗲𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝗮𝘁 𝗘𝗡𝗘𝗧𝗦. - PRRT (177Lu-edotreotide) vs. everolimus in progressive GEP-NETs - 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗣𝗙𝗦 𝗮𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲: 23.9 vs. 14.1 months (HR 0.67) - 𝗕𝗲𝘁𝘁𝗲𝗿 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲: fewer grade ≥3 adverse events - PRRT poised to become a 𝗻𝗲𝘄 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 𝗼𝗳 𝗰𝗮𝗿𝗲 For all ENETS 2025 videos 👇 find the link in the comments!  #MediMix #ENETS2025 #NeuroendocrineTumours #PRRT #Oncology #GEP_NETs #InDepth

The BSMO moved from X to LinkedIn from now on! Please follow us 🤩 https://lnkd.in/eYaMeJY2

🔍 𝗜𝗻 𝗗𝗲𝗽𝘁𝗵 𝗳𝗿𝗼𝗺 𝗘𝗡𝗘𝗧𝗦 𝟮𝟬𝟮𝟱! Prof Dr Timon Vandamme takes a closer look at the pivotal 𝗖𝗔𝗕𝗜𝗡𝗘𝗧 𝘁𝗿𝗶𝗮𝗹, published in NEJM, evaluating 𝗰𝗮𝗯𝗼𝘇𝗮𝗻𝘁𝗶𝗻𝗶𝗯 in previously treated NETs: - Significant 𝗣𝗙𝗦 𝗯𝗲𝗻𝗲𝗳𝗶𝘁 in extra-pancreatic and pancreatic NETs - Up to 𝟭𝟴% 𝗢𝗥𝗥 in pancreatic NETs - 𝗦𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗺𝗮𝗻𝗮𝗴𝗲𝗮𝗯𝗹𝗲 with appropriate monitoring - No OS difference due to 𝘀𝘁𝘂𝗱𝘆 𝗰𝗿𝗼𝘀𝘀𝗼𝘃𝗲𝗿 For all ENETS 2025 videos 👇 find the link in the comments!  #MediMix #ENETS2025 #NeuroendocrineTumours #Oncology #Cabozantinib #NETs #InDepth

🚀 Highlights from ENETS 2025! In our second highlight, Dr Willem Lybaert discusses some of the most impactful studies presented at the congress: - 𝗖𝗔𝗕𝗜𝗡𝗘𝗧 𝗧𝗿𝗶𝗮𝗹: Cabozantinib extends 𝗣𝗙𝗦 𝗶𝗻 𝗴𝗿𝗮𝗱𝗲 𝟯 𝗡𝗘𝗧𝘀, reinforcing its role in previously treated patients. - 𝗟𝗢𝗟𝗔 𝗧𝗿𝗶𝗮𝗹: Combination of 𝗧𝗞𝗜 + 𝗦𝗦𝗔 shows feasibility but requires dose adjustments. - 𝗦𝗦𝗔 𝗙𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀: BACKSOM study investigates 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀 with different SSA injections, while 𝗼𝗿𝗮𝗹 𝗦𝗦𝗔 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 like paltusotine show promising safety data. For all ENETS 2025 videos 👇 find the link in the comments! #MediMix #ENETS2025 #NeuroendocrineTumors #Oncology #PRRT #GEP_NETs 

🚨 𝗟𝗜𝗩𝗘 𝗳𝗿𝗼𝗺 𝗘𝗟𝗖𝗖 𝟮𝟬𝟮𝟱 𝗶𝗻 𝗣𝗮𝗿𝗶𝘀! 🚨 We’re on-site at the 𝗘𝘂𝗿𝗼𝗽𝗲𝗮𝗻 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝟮𝟬𝟮𝟱, where the latest 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵𝘀 𝗶𝗻 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 are being unveiled. Stay tuned as we bring you 𝗲𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗲𝘅𝗽𝗲𝗿𝘁 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗮𝗻𝗱 𝗴𝗿𝗼𝘂𝗻𝗱𝗯𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 straight from the congress floor. 📩 𝗖𝗵𝗲𝗰𝗸 𝘆𝗼𝘂𝗿 𝗶𝗻𝗯𝗼𝘅 - 𝗼𝘂𝗿 𝗳𝗶𝗿𝘀𝘁 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗮𝗿𝗲 𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗼𝗼𝗻! 🎥 𝗘𝘅𝗽𝗲𝗿𝘁 𝘃𝗶𝗱𝗲𝗼𝘀 𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗼𝗼𝗻 - 𝘀𝘁𝗮𝘆 𝘁𝘂𝗻𝗲𝗱! #MediMix #ELCC2025 #LungCancer #Oncology #CancerResearch

🌟 New Episode Alert: "What’s New Doc in Breast Cancer?" 🌟 In Episode 29, Prof Dr Evandro de Azambuja (Institut Jules Bordet) and Dr Kevin Punie (Ziekenhuis aan de Stroom) discuss the PATINA trial, evaluating the addition of palbociclib to anti-HER2 therapy and endocrine therapy (ET) in HER2+/HR+ metastatic breast cancer: ✔️ Significant PFS improvement: 44.3 months vs. 29.1 months (HR: 0.74). ✔️ Higher response and clinical benefit rates observed with palbociclib. ✔️ Safety profile consistent with prior palbociclib studies. ✔️ Regulatory uncertainty: With palbociclib’s patent expiring soon, its registration for HER2+/HR+ disease remains unclear. These findings position the PATINA regimen as a new standard of care for HER2+/HR+ metastatic breast cancer. 👇 View all WND Breast videos - link in the comments! #MediMix #BreastCancer #PATINATrial #Oncology #HER2 #CDK46 #EndocrineTherapy

🚀 Highlights from ENETS 2025! In our first highlight, Prof Dr Timon Vandamme dives into 2 groundbreaking studies: - 𝗖𝗢𝗠𝗣𝗘𝗧𝗘 𝗧𝗿𝗶𝗮𝗹: PRRT (177Lu-edotreotide) outperforms everolimus in progression-free survival, setting a new standard of care. - 𝗢𝗖𝗟𝗨𝗥𝗔𝗡𝗗𝗢𝗠 𝗧𝗿𝗶𝗮𝗹: 177Lu-Dota-Octreotate shows an 𝘂𝗻𝗽𝗿𝗲𝗰𝗲𝗱𝗲𝗻𝘁𝗲𝗱 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗿𝗮𝘁𝗲 (𝟲𝟯%) in pancreatic NETs. - 𝗕𝗲𝗹𝗴𝗶𝗮𝗻 𝗹𝗶𝗾𝘂𝗶𝗱 𝗯𝗶𝗼𝗽𝘀𝘆 𝗮𝘀𝘀𝗮𝘆 for NET diagnosis wins a poster award! 🌟 For all ENETS 2025 videos 👇 find the link in the comments! #MediMix #ENETS2025 #NeuroendocrineTumours #Oncology #PRRT #GEP_NETs

🌟 New Episode Alert: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰? 𝗶𝗻 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿" 🌟Can SLNB be safely omitted in early-stage breast cancer? In Episode 28, Prof Dr Evandro de Azambuja and Dr Kevin Punie discuss the INSEMA trial results, shedding light on a potential shift in surgical management: - No significant difference in 5-year iDFS (91.9% vs. 91.7%) or OS between groups. - SLNB omission is safe in selected patients: Age ≥50, HR+/HER2-, grade 1-2, tumour ≤2 cm, no lymph node involvement. - Exceptions: Grade 3 tumours and lobular histology require further evaluation. These results align with the SOUND trial and could impact future clinical practice. Is it time to rethink SLNB in breast cancer surgery? 👇 View all WND Breast videos - link in the comments! #MediMix  #BreastCancer #Oncology #INSEMA #Oncology #SurgicalOncology #BreastSurgery

🌟 𝗡𝗲𝘄 𝗘𝗽𝗶𝘀𝗼𝗱𝗲 𝗔𝗹𝗲𝗿𝘁: "𝗪𝗵𝗮𝘁’𝘀 𝗡𝗲𝘄 𝗗𝗼𝗰 𝗶𝗻 𝗕𝗿𝗲𝗮𝘀𝘁 𝗖𝗮𝗻𝗰𝗲𝗿?" 🌟 In Episode 27, Prof Dr Evandro de Azambuja and Dr Kevin Punie discuss the latest findings from the GeparDouze trial, evaluating perioperative atezolizumab in early-stage TNBC. - No improvement in EFS: 85.2% (atezolizumab) vs. 81.9% (placebo) (HR: 0.8; p=0.08). - pCR increased from 57.0% to 63.3%, but this did not translate into long-term benefit. - Atezolizumab has no role in  early-stage TNBC. These results reinforce that KEYNOTE-522 remains the standard of care for stage II-III TNBC. 👇 View all WND Breast videos - link in the comments! #MediMix #BreastCancer #GeparDouze #Oncology #TNBC #Immunotherapy

Breast Cancer Highlights of 2024 ✅ Now Available on AccrediMix <https://lnkd.in/dwpXCdYh> - Translational research in breast cancer: what should you not have missed in 2024? - What’s new in radiotherapy for breast cancer? - What’s new in breast cancer surgery? - Advances in the systemic treatment for early-stage breast cancer - Advances in the systemic treatment for advanced breast cancer Register or log in at www.accredimix.be 📌 This educational content is intended for healthcare professionals. #BreastCancer #Oncology #MedicalEducation #AccrediMix #CancerResearch